Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is between 2 and 65 years of age.~* Subject with clinical and histological diagnosis of junctional or dystrophic EB with documented electron microscopy or immunofluorescence microscopy.~* Subject has at least two non-adjacent EB lesions, at least 4 cm apart. The two selected EB lesions must be relatively matched in terms of diagnosis, location, level of erosion and size. Lesions may be on the same limb.~* Subject with dystrophic or junctional EB lesions between 10-44 cm2 present for at least 6 weeks. For the purposes of this study, a lesion is defined as a wound resulting from a post blister erosion.~* Subject who is a female of child-bearing potential (females \>10 years of age) must have a documented negative urine or serum pregnancy test. Sexually active females must be practicing a medically proven form of contraception during the course of the study period.~* Subject or legal guardian must have read, understood and signed an institutional review board (IRB) approved Informed Consent Form or Assent Form.~* Subject and/or legal guardian must be able and willing to follow study procedures and instructions.~Exclusion Criteria:~* Subject with lesions only on the soles, posterior thigh or gluteus maximus.~* Subject whose lesion has healed 20% or greater in area from post debridement (if applicable) Baseline Screen (Visit 1) to post debridement Day 0 (Visit 2) as determined by wound tracings.~* Subject with uncontrolled diabetes mellitus (glycosylated HbA1C \> 10%), cancer (biopsy confirmed active malignancy), or positive HIV test.~* Subject is a child (\<18 years of age) who is currently receiving or has received oral steroid therapy exceeding a total daily dose of 0.5mg/kg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks.~* Subject is an adult (\>18 years of age) who is currently receiving or has received chronic high dose steroid therapy exceeding a total daily dose of 20mg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks.~* Subject who is currently on or has received topical steroidal therapy within 30 days before screening. Inhaled steroids are allowed.~* Subject with the presence of acute infections in the areas intended for treatment.~* Subject with a history of squamous cell carcinoma.~* Known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium.~* Subject who is lactating or pregnant (hCG positive as determined by lab testing).~* Subject is a child (\<18 years of age) with liver (ALT/SGPT, ALP, AST/SGOT, bilirubin, total protein, LDH) and/or renal function (BUN and creatinine) tests \> 2 x upper limit of normal (ULN). Albumin \< 2.0 mg/dL.~* Subject is an adult (\>18 years of age) with liver (ALT/SGPT, ALP, AST/SGOT, bilirubin, total protein, LDH) and/or renal function (BUN and creatinine) tests \> 2 x upper limit of normal (ULN). Albumin \< 2.0 mg/dL.~* Subject enrolled in any wound or investigational device study for any disease within the past four weeks.~* Subject who has received an investigational drug or biological treatment within three months.~* Subject previously treated with Apligraf, Dermagraft or any other cell therapy at the target sites.~* Subject with a history of alcohol or substance abuse within the previous year, which could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes.~* Subject who, in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Apligraf (a living bilayered cell therapy product)
- 2 (Type: ACTIVE_COMPARATOR): Dressing regimen comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues